Takeda Results, Outlook, Eying Late-Stage Pipeline Development, Operating Margin Expansion

 

• Revenue Growth of +5.9% at Actual Exchange Rates (AER); +1.5% at Constant Exchange Rate (CER) Driven by Growth & Launch Products
• Core Operating Profit Change of -13.3% at CER Reflecting Generic Impact and Investment in R&D and Data, Digital & Technology
• Three New Molecular Entity (NME) Approvals from U.S. FDA in FY2023
• Up to Six NMEs with Significant Revenue Potential in Phase 3 Development in FY2024
• Committed to 100-250 Basis Points Core Operating Profit Margin Improvement Each Year from FY2025 Towards Low-to-Mid 30s% Target

https://www.biospace.com/article/releases/takeda-announces-fy2023-full-year-results-and-fy2024-outlook-affirming-commitment-to-late-stage-pipeline-development-and-core-operating-profit-margin-expansion/